NRG Phase II Randomized Trial of Nivolumab with or without Ipilimumab in Patients with Persistent or Recurrent Epithelial Ovarian; Primary Peritoneal or Fallopian Tube Cancer Adult CIRB - Early Phase Emphasis Temporarily Closed to Accrual Available to Open